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ABSTRACT
Introduction: An integrated analysis was
performed using safety data from 18
randomized, parallel-group studies from the
fluticasone furoate/vilanterol (FF/VI) GSK
asthma clinical study program. Efficacy data
from four pivotal studies were also analyzed.
Methods: Data were integrated from 18 Phase
IIb and Phase III clinical studies. Key treatment
arms were FF/VI 200/25 lg, FF/VI 100/25 lg, FF
200 lg, FF 100 lg, VI [with inhaled
corticosteroids (ICSs)] 25 lg, and placebo.
Safety endpoints included adverse events
(AEs), AEs of special interest, 24-h urinary
cortisol, vital signs, electrocardiograms, and
asthma composite endpoints (defined as
asthma-related hospitalizations, intubations, or
death). Key efficacy endpoints included lung
function assessments and symptomatic
measures.
Results: In total, 7229 patients were
randomized to one of six key treatment
groups. The most frequently experienced AEs
across key treatment groups were headache,
nasopharyngitis, and upper respiratory tract
infection. A greater incidence of local steroid
effects was reported with FF-containing
treatment groups versus placebo. No
statistically significant difference was observed
in asthma composite endpoint (asthma-related
hospitalizations, intubations, or death) analysis
of all FF/VI doses versus all ICS doses. A
statistically significant difference in trough
forced expiratory volume in one second
(FEV1), 0–24 h weighted mean FEV1, and
rescue-free and symptom-free 24 h periods was
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reported between FF/VI and FF treatment
groups in all studies except one
(NCT01165138).
Conclusion: There was no evidence of an
increased safety risk associated with FF/VI
versus FF, VI, or placebo. FF/VI improved lung
function and symptomatic endpoints versus FF
alone. These data support the positive
benefit:risk ratio of FF/VI versus FF alone and
of having two approved FF/VI strengths to
ensure appropriate treatment for patients with
different asthma severity.
Funding: GSK.
Keywords: Adverse events; Asthma; Efficacy;
FF/VI; Safety
INTRODUCTION
Asthma is one of the most common chronic
diseases with an estimated 300 million people
diagnosed worldwide [1]. International
guidelines for asthma treatment recommend
the combination of long-acting b2-receptor
agonist (LABAs) with inhaled corticosteroids
(ICSs) as maintenance therapy in patients who
remain symptomatic despite receiving
low-to-medium doses of ICSs [1, 2].
Although many treatment options are
available, asthma morbidity remains high, with
an estimated 346,000 deaths annually worldwide
[1, 3]. Despite treatment, the incidence of
uncontrolled asthma remains high with a recent
European survey of 8000 subjects with asthma
showing that 45% of patients with asthma had
uncontrolled disease [4]. Poor control often limits
activity, and causes breathlessness and sleep
difficulties. Patients with poorly controlled
disease also experience more absenteeism and
work impairment than those with asthma that is
at least well controlled [4].
Asthma-related deaths, increased
exacerbations, and poor disease control have
been associated with non-adherence to
medication [5], which is reported to be
common in this patient population [6, 7]. A
report from the UK suggested that 65% of
asthma-related deaths occurring between
February 2012 and January 2013 were due to
patient-related factors, including
non-adherence to medication [8].
Non-adherence to medication is a key factor
contributing to poor disease control, which
leads to more frequent visits to healthcare
professionals, an increase in healthcare costs,
and a reduction in health-related quality of life
[9] and may be improved with once-daily
dosing [10].
GSK has conducted a large complex program
of Phase II and III clinical studies in more than
12,000 adults and adolescents with asthma to
evaluate the efficacy and safety of fluticasone
furoate/vilanterol (FF/VI), a once-daily ICS/
LABA combination therapy administered as a
single fixed dose using the ELLIPTA dry
powder inhaler (GSK, Brentford, London). Two
doses of FF/VI (200/25 and 100/25 lg) have
been approved as maintenance therapy for
patients with asthma in the USA [11], Europe
[12–14], Japan [15], and a number of other
countries. The availability of two FF/VI
strengths provides flexible treatment options
to meet the individual needs of patients.
This paper presents an integrated analysis of
safety data collected from 18 randomized,
parallel-group studies that were part of the FF/
VI GSK clinical study program. In addition,
efficacy data from four pivotal studies have been
evaluated and will be presented to allow a
benefit:risk assessment, including an
integrated efficacy analysis for forced
expiratory volume in one second (FEV1) by
demographic subgroups. Furthermore, greater
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comprehension of the safety, efficacy, and
benefit:risk ratio of FF/VI, administered as a
single fixed dose in a large patient population,




Four Phase IIb and 14 Phase III randomized,
double-blind, parallel-group studies with FF/VI
and/or an individual component (FF or VI) were
included in this integrated safety analysis. The
study designs are summarized in Supplementary
Table 1; briefly FF/VI (200/25 or 100/25 lg), FF
(200 or 100 lg), and VI 25 lg on a background
of ICSs [VI (ICS) 25] were administered
once-daily in the evening using the ELLIPTA
inhaler. In ten of these studies, active
comparators [fluticasone propionate (FP 500,
250, or 100 lg), salmeterol (SAL 50 lg) on an
ICS background, or FP/SAL (250/50 lg)] were
administered twice-daily using the DISKUSTM
inhaler (GSK, Brentford, London). All active
treatment doses are presented in micrograms
(lg). Patients were provided with albuterol/
salbutamol to be used as rescue medication
throughout the study when and as required.
The key treatment groups in this integrated
analysis were: FF/VI 200/25, FF/VI 100/25, FF
200, FF 100, VI (ICS) 25, and placebo. Only data
from these key groups are presented.
Data from the following 18 clinical studies
were used in this integrated analysis:
NCT00603746 (FFA109684) [16], NCT00603
278 (FFA109685) [17], NCT00603382 (FFA10
9687) [18], and NCT00600171 (B2C109575)
[19] are Phase IIb studies; NCT01165138
(HZA106827) [20], NCT00134042 (HZA106829)
[21], NCT01686633 (HZA116863) [22], NCT010
86384 (HZA106837) [23], NCT01498653 (HZA1
13714) [24], NCT01498679 (HZA113719; data
on file), NCT01147848 (HZA113091) [25],
NCT01436071 (FFA115283) [26], NCT014
36110 (FFA115285) [27], NCT01159912
(FFA112059) [28], NCT01431950 (FFA114496)
[29], NCT01181895 (B2C112060) [30],
NCT01018186 (HZA106839) [31], and NCT01
086410 (HZA106851) [32] are Phase III studies.
Across all studies, eligible patients were
C12 years of age and had been diagnosed with
persistent asthma. Other inclusion criteria
included a predicted pre-bronchodilator FEV1 of
40–90% (C50% in NCT01086410 and
NCT01018186, C60% in NCT01436071 and
NCT01436110, 40–80% in NCT01686633,
40–85% in NCT01147848, and 50–90% in
NCT01086384), and FEV1 reversibility of C12%
and C200 mL within 10–40 min, following
200–400-lg albuterol/salbutamol inhalation. In
addition, all patients in NCT01086384 must
have experienced one or more asthma
exacerbations requiring treatment with oral
corticosteroids in the previous year. This
article is based on previously conducted
studies, and does not involve any new studies
of human or animal subjects performed by any
of the authors.
Safety Analyses
Safety analyses were performed on the
intent-to-treat (ITT) population, which was
defined as all patients who were randomized
and had received at least one dose of study
medication during the treatment period. The
urinary cortisol (UC) population is defined as
the population of primary interest for 24-h UC
analyses. The safety endpoints assessed
included adverse events (AEs), AEs of special
interest (AESIs), 24-h UC, vital signs,
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electrocardiograms, and an asthma composite
endpoint (defined as asthma-related
hospitalizations, intubations, or deaths).
AEs were coded and grouped by system organ
class and preferred term using the Medical
Dictionary for Regulatory Activities (MedDRA
V16.1 [IFPMA (Geneva, Switzerland)]). AEs that
were assessed by the investigator as having a
reasonable possibility of being caused by the
study medication were termed ‘drug-related’.
For all analyses, 95% confidence intervals (CIs)
were used as appropriate. When significance
testing was carried out, a two-sided test was
used at the 0.05 significance level.
AESIs were defined using pre-selected
MedDRA V16.1 preferred terms and based on
the knowndrug class AE profile or pharmacology
of corticosteroids [i.e., hypersensitivity, bone
disorders, local steroid effects (e.g., oral
candidiasis, hoarseness), ocular effects, glucose


















Female 635 (59) 583 (61) 1470 (62) 378 (62) 1290 (64) 129 (60)
Male 435 (41) 373 (39) 899 (38) 230 (38) 720 (36) 87 (40)
Mean age, years (SD) 40.1 (16.36) 44.2 (15.22) 42.3 (16.55) 43.3 (15.43) 42.1 (16.60) 41.5 (16.22)
Age, n (%)
12–17 years 115 (11) 66 (7) 261 (11) 41 (7) 236 (12) 25 (12)
18–64 years 890 (83) 816 (85) 1930 (81) 525 (86) 1630 (81) 177 (82)
C65 years 65 (6) 74 (8) 178 (8) 42 (7) 144 (7) 14 (6)
Race, n (%)
Caucasians 610 (57) 652 (68) 1652 (70) 468 (77) 1550 (77) 141 (65)
Asian 216 (20) 224 (23) 457 (19) 57 (9) 167 (8) 9 (4)
African American 67 (6) 62 (6) 124 (5) 29 (5) 126 (6) 19 (9)
Mixed race 75 (7) 14 (1) 125 (5) 41 (7) 151 (8) 1 (\1)
American Indian 101 (9) 3 (\1) 9 (\1) 13 (2) 12 (\1) 46 (21)
Hawaiian/Paciﬁc
Islander
1 (\1) 0 2 (\1) 0 3 (\1) 0
Ethnicity, n (%)
Hispanic/Latino 213 (20) 85 (9) 317 (13) 129 (21) 341 (17) 57 (26)
Not Hispanic/Latino 857 (80) 871 (91) 2052 (87) 479 (79) 1669 (83) 159 (74)






16.20 (13.29) 17.96 (13.27)
FF ﬂuticasone furoate, ICS inhaled corticosteroid, SD standard deviation, VI vilanterol
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effects, pneumonia, lower respiratory tract
infections, and systemic effects (e.g.,
hypothalamic–pituitary–adrenal axis)] and
LABAs (i.e., cardiovascular effects, effects on
potassium, effects on glucose). Analysis of AESIs
was performed using Cochrane–Mantel–
Haenszel corrected percentages of patients to
compare each FF dose versus placebo, FF/VI
200/25 versus FF/VI 100/25, FF/VI 100/25 versus
FF 100, and FF/VI 100/25 versus placebo.
For the composite endpoint, all serious AEs
(SAEs) for studies that included VI, either as a
monotherapy on a background of ICSs or as part
of FF/VI, were assessed by an independent
adjudication panel blinded to both treatments
whether the event was respiratory-related or not
respiratory-related. Respiratory-related events
were further assessed as being asthma-related
or not asthma-related. Five crossover studies
(NCT01453023 [FFA112777], NCT01128569
[FFA113090], NCT01128595 [FFA113126],
NCT00980200 [FFA113310], and NCT012
87065 [FFA114624]) and an open-label clinical
study (NCT01244984 [FFA113989]), which were
not included in the integrated analysis, were
used (in addition to the Phase IIb and Phase III
studies) in the asthma composite endpoint
adjudication and analysis to ensure that all
available data on VI-containing studies were
included.
Efficacy Analyses
Efficacy data from the following four pivotal
Phase III studies are described: NCT01165138,
NCT01134042, NCT01686633, and
NCT01086384. All analyses were performed
using the ITT population. Key efficacy
endpoints included lung function assessments
(trough and weighted mean FEV1) and
symptomatic measures (rescue- and
symptom-free 24-h periods). Results were
shown as treatment differences, least squares
means, 95% CI, and p values. Due to the
differences between the four studies (i.e., study
design and study populations), efficacy findings
will focus on the individual studies. Data
showing trough FEV1 at week 12 were
integrated to facilitate efficacy evaluation by
the following subgroups: gender, age, race, and
region.
RESULTS
The cut-off date for all data included in this
analysis was 31 January, 2014. A total of 9919
([99%) patients received C1 dose of study
medication (Fig. 1). The ITT population for
this integrated analysis comprised 7229
patients who were randomized to one of the
six key treatment groups: FF/VI 200/25
(n = 956), FF/VI 100/25 (n = 2369), FF 200
(n = 608), FF 100 (n = 2010), VI (ICS) 25
(n = 216), and placebo (n = 1070). The
majority of these patients received either FF/VI
100/25 or FF 100. The VI (ICS) 25 group
contained the smallest number of patients, as
this treatment was only included in two studies.
Across the studies, 84% of patients in the key
treatment groups completed the study and 16%
withdrew prematurely. Lack of efficacy was the
most common reason for withdrawal in all
groups except for FF/VI 100/25; 23% of
patients in the placebo group withdrew citing
this reason. In the FF/VI 100/25 group,
withdrawal of consent was the most common
reason for withdrawal (reported by 4% of
patients). Other reasons for withdrawal, such
as protocol deviation and AEs, were reported by
B2% of patients within each treatment group.
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Demographic characteristics for the key
treatment groups are provided in Table 1. The
proportion of males to females and the mean
age were similar across these groups. The
majority of patients in each treatment group
were aged 18–64 years and the majority were
Caucasian. The mean duration of asthma
ranged from 15 to 18 years.
Cumulative exposure varied widely across
the key treatment groups, which is likely to
reflect the differing duration of these studies
(range of 4–76 weeks). The highest exposure
was reported for the FF/VI 100/25 group (1537
patient years; key treatment groups displayed
in Table 2). More than half (59%) of the FF/VI
100/25 patients were in studies of C24 weeks’
duration. As patients may not receive a
long-term placebo, no patient was exposed to
placebo for more than 28 weeks. Most (63%)
of the patients who were randomized to
receive placebo were in studies of \12 weeks’
duration.
Safety Analysis
The most frequently reported common AEs
were headache, nasopharyngitis, and upper
respiratory tract infection (key treatment
groups displayed in Table 3). The incidence of
some events was numerically higher in the FF/
VI 100/25 group compared with the placebo
group. However, there was no
notable difference in exposure-adjusted
incidence across treatment groups with the
exception of oropharyngeal pain, for which
the incidence was numerically greater in the
FF/VI 200/25 group than the FF/VI 100/25
group, and back pain, which was reported at a
numerically higher incidence in all active
treatment groups compared with placebo.
Figure 2a presents the incidence of AEs
reported by C3% of patients for FF/VI 100/25
compared with placebo (in those studies that
included both FF/VI 100/25 and placebo) and
shows that the incidence is similar (95% CI for
Fig. 1 CONSORT diagram. aVI was administered with a background of inhaled corticosteroids. FF ﬂuticasone furoate,
VI vilanterol
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the risk ratio included 1) for nasopharyngitis
and upper respiratory tract infection, and
favored placebo for headache. When the
incidence of any AE reported by C3% of
patients for FF/VI 100/25 was compared with
FF 100, there was no evidence of a significant
difference as the 95% CI for the risk ratio
includes 1 (Fig. 2b). There is also no evidence
of an increase in the incidence of any AEs
reported by C3% of patients for FF/VI 200/25
compared with FF/VI 100/25 (Fig. 2c).
The incidence of any drug-related AE (based
on investigator opinion) was 6% in the FF/VI
200/25, FF/VI 100/25, FF 200, and FF 100
groups, and 2% in the VI (ICS) 25 group,
compared with 2% in the placebo group
(Table 4). Among the drug-related AESIs, oral
candidiasis had the highest incidence in the FF/
VI 200/25 group (2%) compared with 0% in the
placebo group,\1% in the FF/VI 100/25 and FF
100 groups, and 1% in the FF 200 group. The
incidence of other drug-related AESIs was low
across all groups [dysphonia: 1% with FF/VI
100/25,\1% with FF/VI 200/25, FF 100, FF 200,
and placebo, 0% with VI (ICS) 25;
oropharyngeal candidiasis: 1% with FF 200,
\1% with FF/VI 200/25, FF/VI 100/25, FF 100,
and placebo, 0% with VI (ICS) 25;
oropharyngeal pain: \1% with FF/VI 200/25,
FF/VI 100/25, FF 200, FF 100, and placebo, 0%
with VI (ICS) 25; and bronchitis:\1% with FF/
VI 100/25 and FF 100, 0% with FF/VI 200/25, FF
200, VI (ICS) 25, and placebo].
No differences were observed in the
incidence of SAEs between the FF/VI 200/25,
FF/VI 100/25, FF 200, FF 100, and VI (ICS) 25
groups, and the placebo group (Table 5). Across
the FF/VI 200/25, FF/VI 100/25, FF 200, and FF
100 groups, seven patients experienced SAEs
considered by the investigator to be related to
study medication: one patient in the FF/VI
200/25 group (atrial fibrillation); two patients
in the FF/VI 100/25 group (tachyarrhythmia
and atrial fibrillation); and four patients in the
FF 100 group (non-cardiac chest pain, asthma
exacerbation, pleurisy, and pneumonia). Four
deaths were reported. One patient died in the
FF/VI 100/25 group (road accident) and two in
the FF 100 group (stage IV lung cancer, and
sepsis and pneumonia); none of these was
determined to be asthma-related or considered
to be related to the study medication. One
patient in the placebo group died of an
unknown cause.















Number of patients with
total exposure
1065 954 2369 604 2008 216
\12 weeks, n (%) 674 (63) 276 (29) 388 (16) 327 (54) 493 (25) 152 (70)
C12 weeks, n (%) 391 (37) 678 (71) 1981 (84) 277 (46) 1515 (75) 64 (30)
C24 weeks, n (%) 120 (11) 309 (32) 1400 (59) 180 (30) 1081 (54) 0
C52 weeks, n (%) 0 122 (13) 696 (29) 0 567 (28) 0
Total patient years 214.94 382.16 1537.33 169.15 1253.14 32.42
FF ﬂuticasone furoate, ICS inhaled corticosteroid, VI vilanterol
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The incidences of AESIs across the key
treatment groups are presented in Table 6. The
incidence of local steroid effects was
numerically higher with FF-containing
treatment arms (7–8%) compared with placebo
(2%). The incidence of lower respiratory tract
infection (LRTI) in the FF/VI 200/25 and FF/VI
100/25 groups was 3% and 4%, respectively,
compared with 2% in the placebo group, and
3% and 6% in the FF 200 and FF 100 groups,
respectively, with the rate of bronchitis events
(5%) being the main factor in the FF 100 group.
Symptoms that may be associated with
hypersensitivity reactions were observed at a
similar incidence across the groups [2% with FF/
VI 200/25, FF/VI 100/25, FF 100, and placebo;
\1% with FF 200 and VI (ICS) 25].
The exposure-adjusted incidence of local
corticosteroid effects, pneumonia and LRTIs,
cardiovascular effects, and hypersensitivity
reactions was numerically higher within the
FF/VI 200/25 group versus the FF/VI 100/25
group. A numerically greater exposure-adjusted
incidence of local steroid effects was observed
with FF 200 (283.8/1000 patient years) versus FF
100 (104.5/1000 patient years), and with FF/VI
200/25 (183.2/1000 patient years) versus FF/VI
100/25 (100.8/1000 patient years). A
numerically greater exposure-adjusted
incidence of cardiovascular events was
experienced in the FF/VI 200/25 group (120.4/
1000 patient years) compared with the FF/VI
100/25 group (66.3/1000 patient years). This
was influenced by the higher number of
extrasystoles observed in study NCT01018186
during Holter monitoring, although the events
were not associated with any symptomatic AEs
(investigators were instructed to record all
events of extrasystoles as AEs). As the dose of
VI is similar in both FF/VI 200/25 and FF/VI
100/25, the reason for this discrepancy is
unclear.
Pneumonia was reported by\1% of patients
in any of the key treatment groups.
Investigators determined the diagnosis of
pneumonia and were requested, but not
mandated, to provide X-ray confirmation. Of
the 40 patients in the key treatment groups who
reported a pneumonia event, only 27 patients
received a chest X-ray, and pneumonia was
confirmed by X-ray in 25 of them (Table 7). The
incidence of X-ray confirmed pneumonia was
\1% in all the active treatment groups,
compared with \0.1% in the placebo group
(Table 7). The low number of events in each
treatment group may mean any differences are
difficult to identify. The exposure-adjusted
incidence of X-ray confirmed pneumonia in
the FF/VI 200/25 and FF/VI 100/25 groups was
5.2 and 7.2/1000 treatment years, respectively,
compared with 4.7 in the placebo group, and
5.9 and 7.2 in the FF 200 and FF 100 groups,
respectively (Table 7).
The safety of FF/VI in patients with asthma
was evaluated in subpopulations based on age,
gender, race, and region. The incidences of AEs
in these subgroups were similar to the incidence
in the ITT population across the key treatment
groups.
The change from baseline in heart rate by
treatment group is shown in Fig. 3. The mean
baseline heart rates across the six key treatment
groups ranged from 69.5 to 72.4 beats per
minute. The maximum mean change from
baseline at 24-h pre-dose was \1 beat per
minute for the FF/VI and placebo groups.
Data from ten clinical studies (n = 2547)
were used to assess urine free cortisol excretion
(key treatment groups displayed in Table 8). At
baseline, the geometric means for 24-h UC
excretion ranged from 57.46 to 64.30 nmol/
24 h across the five treatment groups. At the
end of treatment, the 24-h UC excretion
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geometric means were numerically similar to
baseline.
There were no statistically significant
differences in the asthma composite endpoint
(defined as asthma-related hospitalizations,
intubations, or death) analysis of all FF/VI
doses versus all ICS doses (i.e., the 95% CIs for
the difference all included zero; Fig. 4). The
common odds ratio was 0.854 (95% CI
0.344–2.146). Within the subgroup analyses by
race and age, there were no differences between
all FF/VI and all ICS doses. For African
Americans, there was a single composite
endpoint event with FF/VI. In adolescents,
there were four events in the FF/VI group and
two in the ICS group; it is notable that three of
the four events on FF/VI occurred at a single site
bFig. 2 Cochrane–Mantel–Haenszel adjusted commonly
experienced (C3%) on-treatment AEs by relative risk for
a FF/VI 100/25 versus placebo (including:
NCT01165138, NCT01086410, and NCT01498679),
b FF/VI 100/25 versus FF 100 (including:
NCT01165138, NCT01086384, and NCT01686633),
and c FF/VI 200/25 versus FF/VI 100/25 (including:
NCT01018186, NCT01086410, and NCT01686633).
AE adverse event, CI conﬁdence interval, FF ﬂuticasone
furoate, OD once-daily, VI vilanterol
Table 4 Drug-related adverse events occurring in[5 patients across treatment groups












Any drug-related AE 26 (2) 61 (6) 148 (6) 36 (6) 114 (6) 5 (2)
Dysphonia 2 (\1) 9 (\1) 25 (1) 6 (\1) 11 (\1) 0
Oral candidiasis 0 15 (2) 19 (\1) 7 (1) 14 (\1) 0
Headache 5 (\1) 3 (\1) 15 (\1) 0 18 (\1) 1 (\1)
Oropharyngeal
candidiasis
1 (\1) 8 (\1) 3 (\1) 9 (1) 8 (\1) 0
Oropharyngeal pain 2 (\1) 3 (\1) 9 (\1) 1 (\1) 9 (\1) 0
Cough 2 (\1) 0 8 (\1) 1 (\1) 5 (\1) 0
Upper respiratory
tract infection
1 (\1) 0 7 (\1) 0 5 (\1) 0
Muscle spasms 0 1 (\1) 6 (\1) 0 1 (\1) 0
Nausea 1 (\1) 2 (\1) 3 (\1) 2 (\1) 1 (\1) 0
Palpitations 0 3 (\1) 2 (\1) 1 (\1) 1 (\1) 0
Throat irritation 0 0 3 (\1) 2 (\1) 2 (\1) 0
Bronchitis 0 0 4 (\1) 0 3 (\1) 0
Dizziness 1 (\1) 0 1 (\1) 2 (\1) 3 (\1) 0
Laryngitis 0 2 (\1) 1 (\1) 0 4 (\1) 0
Candida infection 0 1 (\1) 3 (\1) 0 2 (\1) 0
Nasopharyngitis 1 (\1) 0 3 (\1) 0 2 (\1) 0
Pharyngitis 1 (\1) 0 1 (\1) 1 (\1) 3 (\1) 0
AE adverse event, FF ﬂuticasone furoate, ICS inhaled corticosteroid, VI vilanterol
Pulm Ther (2016) 2:91–114 101
in Eastern Europe, where the site protocol was
to hospitalize patients with asthma
exacerbations who required treatment with
systemic corticosteroids. One patient was
hospitalized due to an asthma exacerbation,
but did not require treatment with systemic
corticosteroids.
Efficacy Analysis
Data for trough and weighted mean FEV1 for the
four pivotal studies are shown in Fig. 5. There
was a statistically significant difference in
trough FEV1 (p\0.014; Fig. 5a) and 0–24 h
weighted mean FEV1 (p\0.048; Fig. 5b)
between the FF/VI and FF treatment groups in
all studies, with the exception of NCT01165138.
It is notable that in the NCT01165138 study
(which investigated FF/VI 100/25, FF 100, and
placebo), the weighted mean FEV1 was assessed
in just over half (51%) of the population,
whereas all patients in the NCT01686633
study (which investigated FF/VI 200/25, FF/VI
100/25, and FF 100) underwent 24-h serial
spirometry. In the NCT01134042 study, FF/VI
200/25 significantly improved trough and
weighted mean FEV1, peak expiratory flow,
and rescue- and symptom-free 24-h periods
compared with FF 200. When rescue- and
symptom-free 24-h periods were assessed, a
statistically significant difference (p\0.010)
between FF/VI and FF treatment groups was
observed in all studies, with the exception of
study NCT01165138. The analysis of study
NCT01165138 is descriptive only, as the
statistical hierarchy stated that a positive
Table 5 Serious adverse events occurring in[1 patient in any treatment group












Any SAE 7 (\1) 9 (\1) 54 (2) 7 (1) 41 (2) 1 (\1)
Asthma
exacerbation
1 (\1) 1 (\1) 13 (\1) 1 (\1) 9 (\1) 1 (\1)
Pneumonia 1 (\1) 1 (\1) 4 (\1) 1 (\1) 6 (\1) 0
Cholelithiasis 1 (\1) 0 1 (\1) 0 1 (\1) 0
Abscess 0 0 0 1 (\1) 1 (\1) 0
Atrial ﬁbrillation 0 1 (\1) 1 (\1) 0 0 0
Breast cancer 0 0 1 (\1) 0 1 (\1) 0
Hypertension 0 0 1 (\1) 0 1 (\1) 0
Intervertebral disk
protrusion
0 0 0 1 (\1) 1 (\1) 0
Limb traumatic
amputation
0 1 (\1) 0 0 1 (\1) 0
Pyelonephritis 1 (\1) 0 0 0 1 (\1) 0
Subarachnoid
hemorrhage
0 0 1 (\1) 0 1 (\1) 0
FF ﬂuticasone furoate, ICS inhaled corticosteroid, SAE serious adverse event, VI vilanterol
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outcome must be shown for the primary
endpoints of FEV1 to allow interpretation of
the secondary endpoints (Fig. 6) [21]. To
account for multiplicity across treatment
comparisons and key endpoints, a specific
step-down testing procedure was applied,
whereby inference for a test in the predefined
hierarchy was dependent upon statistical
significance having been achieved for the
previous tests in the hierarchy. For study
NCT01165138, statistical significance was
achieved at the 5% level for four of the six
designated primary comparisons at the top of
the hierarchy (FF/VI 100/25 versus placebo and
FF 100 versus placebo for the co-primary
endpoints of trough FEV1 and weighted mean
FEV1), but was not achieved for the primary
comparisons of FF/VI 100/25 versus FF 100 for
these co-primary endpoints. Statistical
significance was not demonstrated by all
primary comparisons and no statistical
inference could be made on the secondary
endpoints (which included rescue- and
symptom-free 24-h periods); therefore, these
are only descriptive.
Integrated efficacy data were utilized to
assess the effects of treatment on trough FEV1
at week 12 in subpopulations. Data from four
key efficacy studies (NCT01165138,
NCT01134042, NCT01086384, and
NCT01686633) were integrated and the
treatments were combined regardless of dose,
so that treatment with FF/VI could be compared
with FF for the subpopulations. Subpopulation
analyses of trough FEV1 demonstrated that the
treatment effect was directionally similar as in
the total ITT population (Fig. 7). The widths of
the CIs are a reflection of the sample size.
Benefit:risk Ratio
The benefit:risk ratio of FF/VI 200/25 versus FF/
VI 100/25 and FF/VI 100/25 versus FF 100 is
shown in Fig. 8. The combination of FF with VI
Fig. 3 Change from baseline in heart rate at a Tmax (data
from: NCT00600171, NCT01165138 [subset],
NCT01134042 [subset], and NCT01018186) and
b pre-dose (data from: NCT00600171, NCT01181895,
NCT01165138, NCT01134042, NCT01498653, and
NCT01498679). FF ﬂuticasone furoate, ICS inhaled
corticosteroid, Tmax time to reach the observed maximum
concentration, VI vilanterol
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showed increased efficacy compared with FF
alone across a range of efficacy endpoints,
including lung function, rescue-free 24-h
periods, rate of asthma exacerbations, and
asthma control [as measured by the Asthma
Control TestTM (ACT) (GSK, Brentford,
London)]. There was a relatively low incidence
of drug-related AEs with FF/VI (6% for both
doses) compared with 2% for placebo; no event
occurred in[2% of patients at either dose of FF/
VI, showing that the combination is associated
with a low risk of events. As shown in Fig. 2b,
there were no relevant differences with the
addition of VI to FF on the incidence of asthma
events and other safety outcomes. In the
clinical setting, having an alternative dose of
an ICS allows treatment to be modified with
differences in disease severity. This ability to
adjust the corticosteroid dose is in agreement
with treatment guidelines for the ICS/LABA
combination products. Comparing the efficacy
of FF/VI 200/25 with FF/VI 100/25, there was a
numerical benefit with the higher strength
versus the lower strength on several efficacy
variables, including lung function, rescue-free
24-h periods, and asthma control (as measured
by ACT). As also shown, comparison of the
safety profile of FF/VI 200/25 versus FF/VI
100/25 supports the positive benefit:risk ratio
of FF/VI 200/25, as we did not observe any
relevant increases in AEs with the higher
strength; these include SAEs and other
potential ICS-related effects. The efficacy and












n 412 336 446 421 440
Geometric
mean
64.30 57.46 58.80 58.32 63.25
CV, % 87 97 98 91 86
End of treatment
n 412 336 446 421 440
Geometric
mean
64.65 57.75 57.04 56.44 61.69
CV, % 95 96 96 90 84
Ratio to baseline
n 412 336 446 421 440
Geometric
mean
1.01 1.00 0.97 0.97 0.98
CV, % 104 113 111 109 107
CV coefﬁcient of variation, FF ﬂuticasone furoate, VI vilanterol
Fig. 4 Asthma composite endpoint for FF/VI at all doses
versus ICS at all doses by a study, and subgroup analyses by
b race and c age. CI conﬁdence interval, FF ﬂuticasone
furoate, ICS inhaled corticosteroid, RD risk difference, VI
vilanterol
c
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safety of FF/VI shows an overall positive
benefit:risk profile for the combination therapy.
DISCUSSION
The integrated safety analyses presented here
provide evidence that FF/VI administered as a
maintenance therapy has a favorable safety
profile in patients with asthma. No
drug-related AEs or safety signals were
identified from these integrated analyses that
were not already established as known class
effects of ICS/LABA combination therapy and
included in the labeling information for FF/VI.
Findings from the efficacy analyses demonstrate
that the once-daily combination of FF/VI
improves lung function and symptomatic
endpoints at both approved doses.
Some potential pharmacological class risks
have been associated with ICSs and LABAs. In
these integrated analyses, an increased
incidence of oropharyngeal pain, dysphonia,
oral candidiasis, and oropharyngeal candidiasis
was observed in the FF-containing key
treatment groups compared with the placebo
group. These effects are known potential risks
associated with ICS use and are included in the
label for FF/VI. A numerically higher
exposure-adjusted incidence of local steroid
effects, cardiovascular effects, and
hypersensitivity reactions was observed in the
FF/VI 200/25 group compared with the FF/VI
100/25 group. It is unclear why there was a
numerically higher exposure-adjusted
incidence of cardiovascular events in FF/VI
200/25 compared with FF/VI 100/25, as the
Fig. 5 a Trough and b weighted mean FEV1 (ml) by study. CI conﬁdence interval, FEV1 forced expiratory volume in 1 s,
FF ﬂuticasone furoate, VI vilanterol
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Fig. 6 Change from baseline in a rescue- and b symptom-free 24-h periods for FF/VI versus FF, by study. *p value is
nominal. CI conﬁdence interval, FF ﬂuticasone furoate, VI vilanterol
Fig. 7 Forest plots for subpopulation analyses of trough
FEV1 (data from: NCT01165138, NCT01134042,
NCT01086346, and NCT01686633). CI conﬁdence
interval, FEV1 forced expiratory volume in 1 s,
FF ﬂuticasone furoate, VI vilanterol
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same dose of the LABA (VI) is included in both
strengths. Cardiovascular events were reported
by 4–5% of patients receiving FF/VI compared
with 3% or less in any of the other key
treatment groups. It is notable that Holter
monitoring was only carried out in the
long-term safety study [31], and this was the
only study to include FF/VI 200/25, FF/VI
100/25, and twice-daily FP 500. The low
incidences of X-ray confirmed pneumonia
observed across all key treatment groups are
consistent with the background rate in the
asthma population, and for FF/VI 200/25, the
exposure-adjusted rates are similar to the
exposure-adjusted rates of pneumonia that
were reported for placebo, FP, and budesonide
in a meta-analysis of data from budesonide
studies [33].
The use of LABA monotherapy in asthma has
been associated with potential increased risk of
serious asthma-related outcomes [34], although
the same concern has not been shown with ICS/
LABA combination therapies [35]. Assessment
of the asthma composite endpoint, comprising
asthma-related hospitalizations, intubations, or
deaths, may help to indicate the risk of
asthma-related deaths with LABA treatment.
There were no differences in the asthma
composite endpoint between the FF/VI
treatment groups and the ICS or non-LABA
group. This demonstrated that the addition of
VI, a LABA, was not associated with any increase
in the frequency of asthma-related events
requiring hospitalization. The risk difference
for patients receiving FF/VI versus patients
receiving ICSs alone was -0.02%, which
represents two fewer hospitalizations per
10,000 patients with FF/VI versus ICSs alone.
These data suggest the risk of asthma-related
events does not increase when VI is used
concurrently with FF.
It is evident that the combination of FF with
VI increases treatment efficacy comparedwith FF
alone, as demonstrated by the improvement in
lung function and increase in rescue-free 24-h
periods (improvement in lung function is
expected with the addition of a LABA). The
higher dose of FF/VI, 200/25, appears to provide
some numerical benefit over FF/VI 100/25 on
several efficacy variables with no additional
safety risk to patients.
This integrated analysis was performed on a
large patient database ([7000 patients), with 46%
of these patients receiving the approved dose of
FF/VI (i.e., 200/25 or 100/25 lg), and consisted of
a rigorous assessment of pharmacologically
predictable effects, such as cortisol suppression
and effects on heart rate, and independent
adjudication for the asthma composite
endpoint. One limitation of this analysis is that
there were differences between the studies in the
populations, treatments, and treatment
durations, which precluded the integration of
efficacy endpoints other than FEV1, at week 12,
such as rescue-free days and withdrawals. The
difference in treatment durations also limits the
interpretation of long-term effects, as the longest
duration of treatment with placebo was 24 weeks
compared with 76 weeks for FF/VI and FF. In the
subgroup analysis by race and age, some
treatment groups were small in size.
Fig. 8 Summary of beneﬁt:risk ratios for a FF/VI 100/25
versus FF/VI 200/25, b FF 100 versus FF/VI 100/25,
c ICS versus FF/VI. ACT Asthma Control TestTM, AE
adverse event, CI conﬁdence interval, FEV1 forced
expiratory volume in 1 s, FF ﬂuticasone furoate, ICS
inhaled corticosteroid, VI vilanterol, WM weighted mean
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CONCLUSION
In this integrated analysis, there was no
evidence of an increased safety risk associated
with FF/VI compared with FF or placebo. These
data support the positive benefit:risk ratio of FF/
VI compared with FF alone. The availability of
two approved strengths of FF/VI offers flexible
treatment options for patients with differing
disease severity, and the single dosing of FF/VI
may improve treatment adherence.
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